SCHEMBL22843420

SCHEMBL22843420

CN(CP)S(=O)(=O)c1ccc(Nc2ccc(C(F)(F)F)cn2)c(-c2cn(C3CC3)cn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 1/20 0.41
▸ YAP1 P46937 1/20 0.41
▸ CCNA2 P20248 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ CCNK O75909 1/20 0.37
▸ CDK12 Q9NYV4 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CCR6 P51684 9/20 0.35
▸ CCR7 P32248 1/20 0.34
▸ NPY5R Q15761 1/20 0.34
▸ TLR2 O60603 1/20 0.34
▸ TLR1 Q15399 1/20 0.34
▸ TNNI3K Q59H18 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ TTK P33981 1/20 0.32
▸ BRAF P15056 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843436 0.97 TEAD1 (0.40) TEAD1YAP1CCNA2CDK2CCNK
SCHEMBL22843401 0.89 TEAD1 (0.39) TEAD1YAP1TLR2TLR1
SCHEMBL22843430 0.88 TEAD1 (0.54) TEAD1YAP1CCNA2CDK2CCNK
SCHEMBL22718447 0.87 CCR6 (0.44) TEAD1YAP1KDM4EMEN1MAPT
SCHEMBL22843424 0.85 TEAD1 (0.42) TEAD1YAP1CCNA2CDK2CCNK
SCHEMBL22718131 0.85 TEAD1 (0.58) TEAD1YAP1CCNA2CDK2CCNK
SCHEMBL22718316 0.84 CCR6 (0.43) TEAD1YAP1MEN1MAPTKMT2A
SCHEMBL29438872 0.84 CCR6 (0.43) TEAD1YAP1MEN1MAPTKMT2A
SCHEMBL22718221 0.82 TEAD1 (0.56) TEAD1YAP1CCNA2CDK2CCNK
SCHEMBL22843482 0.81 CCR6 (0.43) TEAD1YAP1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885CCNA2 3880/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885CCNA2 3880/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885CCNA2 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback